Tarsus expects $670M-$700M 2026 sales as XDEMVY eyes blockbuster $2B+ potential while pipeline advances
Source: SeekingAlpha
2026-02-24 06:16:17 ET
More on Tarsus Pharmaceuticals, Inc.
- Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
- Tarsus Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.20 misses by $0.07, revenue of $151.6M beats by $7.04M
- Seeking Alpha’s Quant Rating on Tarsus Pharmaceuticals, Inc.
- Historical earnings data for Tarsus Pharmaceuticals, Inc.
Read the full article on Seeking Alpha
For further details see:
Tarsus expects $670M–$700M 2026 sales as XDEMVY eyes blockbuster $2B+ potential while pipeline advances
Tarsus Pharmaceuticals Inc.
NASDAQ: TARS
TARS Trading
-2.61% G/L:
$72.79 Last:
247,914 Volume:
$74.26 Open:
TARS Latest News
February 23, 2026 04:05:00 pm
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
TARS Stock Data
$2,815,224,644
38,641,420
0.14%
78
N/A
Biotechnology & Life Sciences
Healthcare
US
Irvine
